The Wnt signaling pathway and its downstream angiocrine target molecules such as FGF23 and DKK2 may also bear therapeutic potential in various types of anemia or in hematopoietic neoplasms. This evidence concerns the gene DKK2 and hematopoietic and lymphoid cell neoplasm.